WELL:XETRA:XETRA-HAN-GINS Indxx Healthcare Megatrend Equal Weight UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 17.226

Change

+0.07 (+0.42)%

Market Cap

USD 0.31B

Volume

233.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.44 (-0.85%)

USD 484.40B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.14 (-0.85%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.23 (-0.83%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.23 (-0.80%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.34 (-1.36%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

-1.28 (-0.89%)

USD 98.29B
JARI:XETRA Amundi Index Solutions - Amund..

-0.34 (-0.73%)

USD 98.25B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.44 (-0.86%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-0.60 (-0.11%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.11 (-0.48%)

USD 79.79B

ETFs Containing WELL:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.61% 93% A 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.61% 93% A 90% A-
Trailing 12 Months  
Capital Gain 47.46% 94% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 47.46% 94% A 93% A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 16.22% 91% A- 87% B+
Dividend Return 16.22% 91% A- 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 24.23% 16% F 27% F
Risk Adjusted Return 66.95% 83% B 84% B
Market Capitalization 0.31B 57% F 51% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.